| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Regular Article |
a Departments of Pharmacology and Therapeutics
b Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada H3G 1Y6
Increases in the survival rate of men treated with chemotherapeutic drugs and their desire to have children precipitate concerns about the effects of these drugs on germ cells. Azoospermia, oligospermia, and infertility are common outcomes resulting from treatment with cyclophosphamide, an alkylating agent. Exposure of male rats to cyclophosphamide results in dose-dependent and time-specific adverse effects on progeny outcome. Elucidation of the effects of chronic low-dose cyclophosphamide treatment on the expression of stress response genes in male germ cells may provide insight into the mechanisms underlying such adverse effects. Male rats were gavaged with saline or cyclophosphamide (6 mg/kg) for 4–5 wk; pachytene spermatocytes, round spermatids, and elongating spermatids were isolated; RNA was extracted and probed on cDNA arrays containing 216 cDNAs. After saline treatment, 125 stress response genes were expressed in pachytene spermatocytes (57% of genes studied), 122 in round spermatids (56%), and 83 in elongating spermatids (38%). Cyclophosphamide treatment reduced the number of genes detected in all germ cell types. The predominant effect of chronic cyclophosphamide exposure was to decrease the expression level of genes in pachytene spermatocytes (34% of genes studied), round spermatids (29%), and elongating spermatids (4%). In elongating spermatids only, drug treatment increased the expression of 8% of the genes studied. The expression profiles of genes involved in DNA repair, posttranslational modification, and antioxidant defense in male germ cells were altered by chronic cyclophosphamide treatment. We hypothesize that the effects of cyclophosphamide exposure on germ cell gene expression during spermatogenesis may have adverse consequences on male fertility and progeny outcome.
1 Supported by the Canadian Institutes of Health Research (CIHR).
2 Correspondence: B. Robaire, Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Montréal, QC, Canada H3G 1Y6. FAX: 514 398 7120; brobaire{at}pharma.mcgill.ca
This article has been cited by other articles:
|
|
 |
|
  A. M. Codrington, B. F. Hales, and B. Robaire Chronic Cyclophosphamide Exposure Alters the Profile of Rat Sperm Nuclear Matrix Proteins Biol Reprod, August 1, 2007; 77(2): 303 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.M. Codrington, B.F. Hales, and B. Robaire Exposure of male rats to cyclophosphamide alters the chromatin structure and basic proteome in spermatozoa Hum. Reprod., May 1, 2007; 22(5): 1431 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Delbes, B. F. Hales, and B. Robaire Effects of the Chemotherapy Cocktail Used to Treat Testicular Cancer on Sperm Chromatin Integrity J Androl, March 1, 2007; 28(2): 241 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aguilar-Mahecha, B. F. Hales, and B. Robaire Effects of Acute and Chronic Cyclophosphamide Treatment on Meiotic Progression and the Induction of DNA Double-Strand Breaks in Rat Spermatocytes Biol Reprod, June 1, 2005; 72(6): 1297 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Hales, T. S. Barton, and B. Robaire Impact of Paternal Exposure to Chemotherapy on Offspring in the Rat J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 28 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, R. Thuillier, and M. Culty Prenatal Estrogen Exposure Differentially Affects Estrogen Receptor-Associated Proteins in Rat Testis Gonocytes Biol Reprod, November 1, 2004; 71(5): 1652 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Barton, A. J. Wyrobek, F. S. Hill, B. Robaire, and B. F. Hales Numerical Chromosomal Abnormalities in Rat Epididymal Spermatozoa Following Chronic Cyclophosphamide Exposure Biol Reprod, October 1, 2003; 69(4): 1150 - 1157. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
